Pharmafile Logo
Pharmafocus logo
Advanced Search

Kidney cancer

Showing 15 posts of 31 posts found.

NICE knocks back advanced kidney cancer drug duo

August 14, 2017
Sales and Marketing Cancer, Kidney cancer, NICE, medicine, pharma, pharmaceutical

NICE has dished out a double judgement turning down two drugs for advanced renal cell carcinoma, a form of kidney …

News

Ipsen secures NICE approval for multi-targeting kidney cancer therapy

July 11, 2017
Manufacturing and Production, Sales and Marketing Cabometyx, Kidney cancer, NICE

Ipsen has announced that its therapy Cabometyx (cabozantinib) has been given approval by NICE for the treatment of advanced renal …

News
pfizer_building

Pfizer says its Sutent meets primary endpoint in Phase III trials for kidney cancer recurrence

July 11, 2016
Research and Development, Sales and Marketing Kidney cancer, Pfizer, Stutent, drug trial

US pharma giant Pfizer (NYSE: PFE) said late-stage trials for its Sutent (sunitinib) met its primary endpoint as a treatment …

News
Eisai logo

FDA grants Eisai’s Lenvima priority review for kidney cancer

January 19, 2016
Manufacturing and Production Breakthrough Therapy Designation, Eisai, FDA, Kidney cancer, Lenvima, lenvatinib, priority review, renal cell carcinoma

The FDA has accepted Eisai’s supplemental New Drug Application (sNDA) for its anti-cancer agent Lenvima for use in the treatment …

News
Opdivo

Bristol-Myers Squibb notches kidney cancer first with Opdivo

September 28, 2015
Research and Development Afinitor, Bristol-Myers Squibb, Kidney cancer, advanced kidney cancer, everolimus, nivolumab, opdivo, renal cell carcinoma

Bristol-Myers Squibb has announced positive results from a Phase III study comparing Opdivo to Afinitor, the Novartis treatment that is …

News

FDA grants Opdivo breakthrough status for kidney cancer

September 18, 2015
Research and Development, Sales and Marketing BMS, Breakthrough Therapy Designation, Bristol-Myers Squibb, FDA, Kidney cancer, immuno-oncology, immunotherapy, nivolumab, opdivo, renal cell carcinoma

The FDA has given Bristol-Myers Squibb’s immuno-oncology drug Opdivo Breakthrough Therapy Designation as a kidney cancer treatment. The FDA’s decision …

News
Opdivo

BMS halts Opdivo kidney cancer trial early

July 22, 2015
Research and Development BMS, Bristol-Myers Squibb, European Commission, Kidney cancer, opdivo, renal cell carcinoma

Bristol-Myers Squibb has stopped its Phase III study of its immunotherapy drug Opdivo in people with kidney cancer early after …

News
Inlyta image

NICE U-turn on Pfizer drug Inlyta

March 5, 2014
Research and Development, Sales and Marketing Kidney cancer, NHS, NICE, Pfizer, axitinib, inlyta

NICE has recommended that Pfizer’s kidney cancer drug Inlyta should be used for some patients in England, following a similar …

News
Novartis' Afinitor (everolimus)

NICE unimpressed with Novartis’ patient access scheme

April 19, 2011
Sales and Marketing Afinitor, Kidney cancer, NICE, Novartis

Novartis has been dealt a blow by NICE after the cost-effectiveness body finally refused to recommend, on appeal, its kidney …

News
Roche's Avastin (bevacizumab)

NICE yes for Votrient, no to Avastin

February 23, 2011
Sales and Marketing Cancer, GSK, GlaxoSmithKline, Kidney cancer, NICE, Roche, avastin, bevacizumab, breast cancer

NICE has recommended GlaxoSmithKline’s kidney cancer drug Votrient on the same day it gave a final negative decision to Roche’s …

News

Astellas to commercialise new kidney cancer drug in Europe

February 21, 2011
Sales and Marketing Astellas, Aveo Pharmaceuticals, Cancer, Kidney cancer, rcc, renal cell carcinoma, tivozanib

Astellas and Aveo Pharmaceuticals are to commercialise Aveo’s investigational kidney cancer drug tivozanib in Europe and the US. Aveo is …

News
Novartis’ Afinitor (everolimus)

Novartis fails to sway NICE with Afinitor deal

November 26, 2010
Sales and Marketing Afinitor, Kidney cancer, NICE, Novartis, advanced renal cell carcinoma, everolimus

Novartis has failed to convince NICE that its revised patient access scheme for Afinitor would make the kidney cancer drug …

News

Pfizer’s axitinib impresses in head-to-head trial with Nexavar

November 22, 2010
Research and Development, Sales and Marketing Kidney cancer, Nexavar, Pfizer, axitinib, mRCC, metastatic renal cell carcinoma

Pfizer’s axitinib has impressed in phase III trials assessing its efficacy as a second line treatment for renal cell carcinoma. …

News

GSK tipped to lead kidney cancer market

July 1, 2010
Sales and Marketing Kidney cancer, Patorma, Votrient, rcc

GlaxoSmithKline’s kidney cancer drug Votrient has been forecast as a future leader in a marketplace currently dominated by Pfizer. Analysts …

News

GSK’s Votrient approved in Europe

June 16, 2010
Sales and Marketing GlaxoSmithKline, Kidney cancer, Votrient

The European Commission has granted a conditional marketing authorisation for a GlaxoSmithKline drug that treats the most common form of …

News

Latest content

Merck shares data from phase 3 trial of Keytruda for gastric cancers

May 2, 2024

Verona Pharma to share phase 3 COPD trial data at ATS 2024

May 2, 2024

Beckman Coulter Life Sciences and Watchmaker Genomics enter collaboration

May 1, 2024

Veru announces first patients enrolled in phase 2b trial for weight loss treatment

May 1, 2024

Bayer and Evotec to collaborate on precision cardiology

April 30, 2024